← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Midwestern University
Downers Grove, IL
$21,193,614
Total funding
59
Grants
Funding over time
peak $2.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,361,173 · 46
NSF$2,378,429 · 12
USDA$454,012 · 1
By mechanism
R15$8,016,580 · 32
R01$6,121,234 · 4
—$2,832,441 · 13
R21$2,217,236 · 6
RF1$1,764,145 · 1
R03$241,978 · 3
Investigators at Midwestern University
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Largest grants
MicroRNA as a Novel Therapeutic Target for Pain in Sickle Cell Disease$1,764,145
RF1 · FY2025 · NS
Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia$726,426
R01 · FY2022 · AI
Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia$669,238
R01 · FY2024 · AI
Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia$669,238
R01 · FY2023 · AI
Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia$669,238
R01 · FY2025 · AI
Unraveling the anatomical and molecular adaptations of primate touch$625,000
· FY2022 · SBE
Mechanism(s) of CD8 T cell-mediated Chlamydia-induced reproductive pathology$459,396
R15 · FY2013 · AI
Elucidation of an informed drug dosing scheme to minimize kidney injury$458,764
R15 · FY2014 · AI
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** CRYPTOSPORIDIOSIS POSES A GLOBAL PUBLIC HEALTH THREAT CHARACTERIZED BY LIFE-THREATENING DIARRHEA IN NEONATES, BUT SEVERE CLINICALDISEASE IN ADULT CATTLE AND PEOPLE IS UNCOMMON. DESPITE SUBSTANTIAL IMPACTS ON THE HEALTH AND ECONOMY OF THE CATTLE INDUSTRY AND THE PUBLIC, EFFECTIVE PREVENTATIVE AND THERAPEUTIC INTERVENTIONS ARE LACKING. THIS IS, IN PART, DUE TO GAPS IN OUR UNDERSTANDING OF HOW CRYPTOSPORIDIOSIS CAUSES DISEASE DIFFERENTLY IN NEONATES COMPARED TO ADULTS, AND A LACK OF ROBUST MODELS TO STUDY THIS DISEASE. INTERACTIONS BETWEEN INTESTINAL CELLS, IMMUNE CELLS, AND FACTORS IN THE TISSUES SERVE AS THE FIRST LINE OF DEFENSE AGAINST CRYPTOSPORIDIOSIS AND ULTIMATELY DETERMINE THE SEVERITY OF THE DISEASE. THE OBJECTIVE OF THIS WORK IS TO: 1) IDENTIFY NEW TARGETS FOR TREATING CRYPTOSPORIDIOSIS BY UNRAVELING THE IMPACT OF AGE (CALVES VS. ADULTS) ON THE DEVELOPMENT OF PROTECTIVE IMMUNITY TO CRYPTOSPORIDIOSIS AND 2) TO VALIDATE AN AGE-SPECIFIC MODEL TO STUDY CRYPTOSPORIDIOSIS. THIS PROJECT HYPOTHESIZES THAT THESE IMMUNE INTERACTIONS (CELLS AND TISSUE FACTORS) WILL DIFFER IN MAGNITUDE AND TYPE IN CALVES COMPARED TO ADULT CATTLE IN AN AGE-DEPENDENT MANNER. THIS WORK WILL ADVANCE OUR KNOWLEDGE OF HOW THE IMMUNE SYSTEM DEVELOPS IN CALVES' OVERTIME AND WILL DETERMINE HOW IMMUNE SYSTEM DEVELOPMENT CONTRIBUTES TO AGE-RELATED SUSCEPTIBILITY TO INFECTION. IN DOING SO, THIS STUDY WILL IDENTIFY PREVENTATIVE AND THERAPEUTIC TARGETS THAT WILL LATER BE EVALUATED FOR EFFICACY. FURTHER, THE ROBUST MODEL AND APPROACH USED HERE WILL SUPPORT AN INVESTIGATION INTO HOW OTHER INFECTIOUS AGENTS CAUSE DISEASE AND PROMOTE THERAPEUTIC DISCOVERY FOR COUNTLESS OTHER INFECTIONS IN CATTLE.$454,012
· FY2021 · National Institute of Food and Agriculture
Mechanism(s) of CD8 T cell-mediated Chlamydia-induced reproductive pathology$450,000
R15 · FY2016 · AI
The role of SWI/SNF chromatin remodelers in homologous recombination and genome stability$449,330
R15 · FY2022 · CA
Prdm16 and Mecom in mouse embryonic mandible and palate development.$446,940
R15 · FY2014 · DE
Mechanisms of cadmium-induced dysglycemia$446,697
R15 · FY2017 · ES
TARGETING ENDOTHELIAL DYSFUNCTION IN A GENETIC MOUSE MODEL OF AORTIC ANEURYSM: IMPLICATIONS FOR PREVENTION AND THERAPY$441,049
R15 · FY2019 · HL
Blending Dentin to Dentin: Biometric Hydrogels for Dentin Tissue Engineering$421,800
R15 · FY2023 · DE
The Role of 12-Lipoxygenase in Aldosterone Secretion$417,791
R15 · FY2015 · HL
Structure-function analysis of zebrafish encoded 3-OST enzyme for HSV-1 Entry$363,742
R15 · FY2011 · AI
Testing Adaptive Hypotheses of Plio-Pleistocene Hominin Craniofacial Evolution$330,021
· FY2021 · SBE
Collaborative Research: Discontinuous Gas Exchange in Insects$320,488
· FY2004 · BIO
Development and Evaluation of CRRT-Specific Precision Dosing Models to Optimize Beta-Lactam Treatment for Patients with Hospital-Acquired Pneumonia$265,427
R21 · FY2023 · AI